1

Similar documents
生活設計レジメ

44 4 I (1) ( ) (10 15 ) ( 17 ) ( 3 1 ) (2)

I II III 28 29



技能継承に関するアンケートの結果概要




i


Wide Scanner TWAIN Source ユーザーズガイド

86 7 I ( 13 ) II ( )

報告書.PDF

第1部 一般的コメント

第1章 国民年金における無年金

untitled

表1票4.qx4

福祉行財政と福祉計画[第3版]

橡ミュラー列伝Ⅰ.PDF

1 (1) (2)

- 2 -


PR映画-1

II III I ~ 2 ~

中堅中小企業向け秘密保持マニュアル



o 2o 3o 3 1. I o 3. 1o 2o 31. I 3o PDF Adobe Reader 4o 2 1o I 2o 3o 4o 5o 6o 7o 2197/ o 1o 1 1o


奄美地域の自然資源の保全・活用に関する基本的な考え方(案)


untitled


untitled

2016 AI : M AI AI AI AI 1980 AI AI AI AI AI AI AI


第1章 製薬産業を取り巻く環境変化

provider_020524_2.PDF


untitled


「産業上利用することができる発明」の審査の運用指針(案)

Microsoft Word - 【061115】用語集(案).doc



YC41S213.ec Jpn Pharmacol Ther vol. 41 supplement 2013 A Proposal for Optimization of Clinical Trial by Central Monitoring System Consolidat

:

178 5 I 1 ( ) ( ) ( ) ( ) (1) ( 2 )

untitled

PowerPoint プレゼンテーション

untitled

[ ]{木山(判例)}(責)魏.indd

2


, 2. 1,,.,,,.,. 1,,, 4.,, GDP, CPI,.,.,., SNA. SNA, SNA. SNA, SNA. 1,, SNA,,, SNA. SNA,,,,,., 1, SNA,,. SNA,,.,,,.,, SNA,.,, 30

untitled

病院広報7_1pol.ai

ii


untitled

untitled

i

untitled

3.....ren

AccessflÌfl—−ÇŠš1

untitled

. 2


松竹映画ファンド重要事項説明書

2

NC! 1 1 1/1000

...J QX

3

CEO COO ,665 SEVENELEVENHAWAII, INC. SE 7Eleven, Inc ,114,0131 2,213,298, , , ,

2 27 4,200 1,890 8,400 14, /

幸せな未来のために

I II III IV A B C V.


スライド 1



縺・・縺。謔縲・シ冗ャャ・難シ仙捷


untitled

1 3 IT I. (1) (1) 2

飯能市と名栗村の新しいまちづくり計画に関する住民意識調査

大学等における社会人の受け入れ状況調査

淡路市環境基本計画 資料編 Web版

untitled

3.3.3 Q1 3R SA 3R R R 237 1,


ito.dvi

ヴェトナムの旅から

?!!!!

(1)...3 (2)...5 (3)...6 (4) (1)...9 (2)...10 (3)...13 (4) 14 (5) (1)...16 (2) (1)...21 (2)...22 (3)

< F2D E8AEE967B95FB906A8DC58F492E6A7464>

1. 2


32

Transcription:

1

3 2008 4 19 69 20 82 12241251 IRB IRB CRC CRC 2000 EDC 2

baseline 19 20 Network draft protocol feasibilitystudy 20 CCR 1 9 timeline 40 coordinating centre Minnesota e-learning seminar 3

114 125 144 67 70 73 476 399 483 303 229 206 79.9 83.8 87.4 80.6 88.0 87.3 4

34 4 (1) IMCJ 2500 (2) 200 90 5 CRC MRC (3) 19 27 20 60 DM JCRAC DMC (4) Central IRB (5) 19 20 25 32 76% 86% 116 96 PMDA IT 5

2 5070 8 DM DM CRC 10 80 IRB IRB IRB IRB 1 / PC FileMaker 1 2 6

18 22 18 19 20 12 4 6 80 26 38 3 856571 IRB 19 4 16 258 27 13 21.8 21 IRB 25.0 13 10.2 11 3 3 20 3 21 5 EMEA 19 24 20 33 4 CRC3 DM3 1 1 1 21 7

2 19 1 CRC15 5 20 59 265 207 52 31 21 9 15.3 % 19 6 20 10 Translational TMC Medical Center, 3 8 3 TMC 8

1. (1) H19 79 39 40322 124 198 18 80 71.4H20 88 26 62378 151 227 26 64 74.4H17 50 H18 55 H19 24 5 2 1 (2) IRB 20 IRB 1117 17 7 (3) H19 179 H20 165 H19 56 H20 67 H19 0 H20 5 H19 103 H20 68 H19 2 H20 11 / H19 18 H20 14 70 2. ARO 6 DM11 OJT 24 e- 5 500 170 ARO (HITCANDIS) 100 TR CRC 3 IRB 3. 18 7 40 11 186 81.2 CRC TV CRC 4. NPO 9

NHO GCP NHO NHO CRB NHOCRB NHO CRC NHO 20 20 NHO EBM 20 26,541 10

19 20 21 IRB 14 IRB 1 5 11

8 2008 9 IRB SOP 2009 2007 28 2008 20 2 2007 2008 8 PMDA 2009 5 2009 6 30 CRC 12

IRB 28 17 4 12 20 10 5 EC HIV 13 National Lead Investigator Asian Study CRC 8 4 LDM1 5 13

60 19 8090 16 21 28 20 IRB EDC CRC 55 JCOGWJOGJGOG 20 CRC3 1 14

18 2006 9 370 600 30 10 2008 3 11 2009 38 2008 69.3 2008

(70 ) () (

H18 10 86 H19 24 200 H20 21 /195 H18 20 335 H19 7 82 H20 13 /80 74.975.671.3 HP 2008 3 ( ) H18 142 H20 109 34 H19 54 46 H20 64 44 CRC H19 3 IT H19 H20 H20 EDC medidata RaveI nformeclinical TM IRB DVD H19 2 /14 H20 2 /9 5 /39 H18 1 /10 H19 1 /6H20 2 /35 H16 2 30 9.46 H19 10 H20 11

9 1838 1,020 12504,000 5 30-40200- 300 500-600 9 42 203862% 72%65% CRC 202 CRC2 21 PhRMA Duke PMDA FDA MHRA IT IT IRB I RB ( 3,171

19 12 ( 20 1 CRC IT 20 2 21 1 2 21 4 learning CRC 18 19 50 20 70 20 CRC 18 19 20 IRB SDV 18 2 19 3 20 4 CRC CRC 1) 19 12 26 2) 3) IRB 19 20 20 11

2007 7 1) i. 4 1. 4 IRB IRB 2. 4 IRB 3. 4 4. 4 4 20083 IRB 10 20091 2009 2 IRB 2009 3 IRB 5 ii. 4 2008 4 2008 12 20094 2) i. 2006 5 1 4 10 48 2007 7 10 2 9 52 2008 21 0 0 21 107 ii. 2006 110 71.8%2007 39 92.3% 2008 130 74.6% 3 279 76.0% iii. ( ) 7 2006 2007 2008 35 32 37 2002 iv. CRC 19982008 132 CRC 80 41 11 108 24 17 1521 22 814 67 39 14 12 v. 2007 11 3 8 2008 12 10 2 CRC 3) 2009 4 74% 15 30 7 1,163

804 2006 1 2008 49.3% 1999 4 CRC10 ( 8 2 )CRC 1 ( 1 ) 5 ( 2 3 ) 3 1 2 2 30 2007 135 2008 143 CRC 2007 2008 260 199 76.5% 32 186 118 63.4% 2008 35.1 27 40 IRB 9.2 5 19 IRB 11.5 5 33 64.7 4 468 1 45.4 8 176 CRF 67.4 56 278 2007 2008 8 80 2 6 74 1 CRC 2 (2008 ) CRC 10 (2008 ) CRC2CRC 2 http://www.tokai-chiken.jp/index.html IRB 11 3 2 (2008 ) 2 )92%(3) 63%(11 )72%(3 ) 1999 4

19 () FPI ( ) ( ) H. 18 33 149 62.4 18 1 1 1 1 H. 19 18 98 65.3 14 1 0 244 (17) (81) 3 2 H. 20 19 65 60.0 6 1 0 238 (2400) (221) 21 7080 19 1 20 2 1 19 20 21 IRB SDV 8

20 20 30 60 100 9 1 IRB 2-3 7 20 85 73 1 CRC3 CRC CRC 3 CRC 3 IT 20

2006 23 99 2007 23 110 2008 22 146 75.7%65.1%68.5% 3 49 42 36 106 98 62 CRC 19 20 4 CRC 1 1 2 21 CRC 2 On the Job Training 4 80

181920 847890 363339435 20 65.876.175.8% 18 10 19 1 3 80% 3 IRB 5 3 181920 185178216 11681144 18 11 19 13 1 11 IT 20 )) 19 2 21 7 2009

2005 CRC IT 3 50% 80% 3 IRB 20 28 32575561 59.3% 76.9% IRB 19 14 CRC CRC 6 0 10.5 43 8.5 23 33 333 177075 753 IRB LDM CDM

Base Line48,394,73.1 19 29,242,83.520 25,145,81.4 BL 15 20 39 43 47 38 46 36 6 17 9 27 50 1617 18 48 394 80% IRB 4 IRB CRC WJOG 19 104 20 135 46.0%, 10.9% 49.4%, 2.1% 4.6% CRC( ), CRC() 1 IT CE IT Excel PDF Net Net SDV PDA SDV SDV

( 1981 363 100 1 2003 最 小 値 )

18 19 20 392331 787076 20 113167191 20 CRC 59 20 8 Web CRC CRC IRB IT HL7 3 8 3

18 20 323030 75 71 53 20 IT 19 20 142 176 CRF DM 20 IRB 1 2 3 19 2 CRC 20 5 SoCRA CRC 0 1 19 1 PMDA DM1 1 CRC 21 CRC 1 10 IT IT 3 HL7 e-crf 19 PDF J-STARS

IRB FPI 18 20 20 IT IRB 19 92 20 163 IRB IRB IRB IRB GCP IRB Web Web IT HL7 CRF e- CRF 100 20 129 IRB GCP 19 52 20 88

IRB FAXRDC LAN CRC

3 3 2 HTR 19 CPC GMP HTR 16 GMP (1 ) (1 ) (1 PMDA (2 ) 600 195 web 172 HTR HTR OJT HTR 3 HTR HTR IT HTR 3 HTR HTR CDISC

1 1 2 TRC in CRF TR TR TR 21 2 TR 3 6 3 0 1.0 TR 5.0 7.0 1.0 1.0 7 7 0.1 1.0 IT CRC TRC, CPC CPC OJT 1.0 1.0 0.4 1.0 0 1.0 2.0 2.0 1.5 1.5 1.0 3.0 2.0 2.0 0.2 1.0 OJT 1.0 1.0 TR TR TR 5.0 5.0 4

1 TR TR TR 1 TR TR TR TR TR TR TR TR CPC CPC GMP cgmp GMP SOP TR TR TR TR TR TR TR 2 12 CD26 3 TR TR

SOP DM GMP 20 GMP DDS GMP ER/ES ER/ES 8 6 5 GMP GMP 2 Research,, TR

TR TR 2003 4 GMP GLP GLP TR 2 CPC GMP GLP TR CPC 11 WT1 HVJ-E IL-6 6

10 2 1 GMP 2 4 2 3 Open(TR) TR TR MEDEC CBDMICBMA-CPCTRI IBRI TR GMP TR TR TR TR TR TR 51

52